Insulin/IGF1-IRS-PI-3 kinase-mtor signaling pathway
|
|
- Shauna Nelson
- 6 years ago
- Views:
Transcription
1 Insulin/IGF1-IRS-PI-3 kinase-mtor signaling pathway Nutrients RAPAMYCIN (FKBP12) mtor/rictor complex phosphorylates Akt at the S473 activating site in a Rheb-independent fashion
2 TSC1 or TSC2-null MEFs show reduced IRS1 and decreased insulin activation of Akt that is reversed by rapamycin Rapamycin treatment for 24 h prior to insulin treatment for 5 min This suggests that there is a negative feedback loop requiring mtor
3 Feedback loop reduces insulin signaling in TSC-null cells S6K feedback downstream of mtor leads to reduction IRS1/2 levels in TSC-null cells (also in LKB1-null cells) IRS1 and IRS2 are less stable in TSC1 and TSC2-null cells - proteasome inhibitor treatment partially restores IRS levels indicating that turnover is through a ubiquitin/proteasome-mediated process IRS1/IRS2 mrna levels are reduced in TSC1 and TSC2-deficient cells and are restored by rapamycin treatment, implying that there is also feedback at the level of transcription TSC-deficient cells are insulin resistant and susceptible to apoptotic stimuli due to defective IGF-1 survival signaling Shah et al. Curr Biol 14:1650 (2004)
4 Model for Rheb/mTOR/S6K negative feedback on IRS function Activated Rheb/mTOR/S6K signaling downregulates IRS function at three levels 1. Inhibition of IRS PTB binding to the activated InsR by direct S6K phosphorylation of Ser (S307) in the PTB domain and other sites (S527), and indirectly other S6Kdependent Ser.Pro sites (S312, S616, S636) contribute to downregulation of IRS signaling (fast) 2. Enhanced degradation of IRS1/2, which is likely phosphorylation dependent (slow) (multiple Ser?) 3. Reduced transcription of IRS1/2 genes by an unknown pathway (slow) (nuclear p85 S6K?) NUCLEUS ENERGY DEPLETION Harrington, Lamb et al. JCB 116:213 (2004) Um, Thomas et al. Nature 431:200 (2004) Shah et al. Curr Biol 14:1650 (2004)
5 TSC2-null cells are sensitized to DNA damage and undergo apoptosis Cells in serum free medium for 6 h with or without growth factor Cells in 0.4% serum overnight and then IGF1 for 4 h followed by camptothecin for 24 h Camptothecin or etoposide-induced apoptosis in TSC1 or TSC2-null cells is largely blocked by rapamycin pretreatment for 24 hours
6 Hypersensitivity of TSC-null cells to DNA damage-induced apoptosis is blocked by rapamycin inhibition of mtor The defect in Akt activation and downstream survival responses could be responsible for the sensitivity of TSC-null cells to DNA-damaging agents
7 + 53 /- -p /+ p5 TS C1 + C1 TS /+ 3+ /+ /- 53 /- -p C2 TS TS C2 + /+ p5 3-/( W T) TSC1/2-deficient MEFs show increased sensitivity to TNFα-induced apoptosis as well as DNA damage Control MMS M M TN S Fα M M S TN Fα TNFα+CHX Cleaved Caspase3-Asp175 Cleaved Caspase3-Asp175 TSC2+/+ TSC2-/- TSC2+/+ untreated TSC2+/+ MMS TSC2-/untreated TSC2-/MMS NF-κB induction by cytokines provides an important survival response
8 NF-κB activation pathways in inflammation and survival NF-κB/IκB families RelA = p65 Bcl-X L, ciaps, GADD45, SOD2 Karin and Greten Nat Rev Immunol 5:749 (2005)
9 Reduced NF-κB activation/nf-κb-dependent gene expression in TSC2 - / - MEFs in response to DNA damage and TNFα TSC2 + / + TSC2 - / - TSC2 + / + TSC1 - / - TSC2 - / - NF-κB EMSA (p65/p50) Oct-1 EMSA TSC2 + / + TSC2 - / - p65 TNFα IL LPS MMS Dox IκBα actin NF-κB target genes
10 Negative feedback reduces insulin signaling in TSC-null cells sirna depletion of TSC1/2 or overexpression of Rheb leads to sustained mtor activation
11 sirna depletion of TSC2 or Rheb overexpression in HEK293 cells attenuates NF-κB-dependent gene expression following DNA damage Control sirna TSC2 sirna TSC2 actin Control transfection Rheb-myc myc actin NF-κB target genes
12 sirna depletion of TSC2 or Rheb overexpression in HEK293 cells also attenuates NF-κB activation and NF-κB dependent gene expression following TNFα treatment sirna depletion of TSC2 in U2OS, MDA-MB-468 and MCF7 human cancer cells causes reduced MMS and TNFα induction of NF-κB target genes
13 Reconstitution of TSC2 restores NF-κB activation and NF-κB dependent resistance to DNA damage/tnfα-induced cell death TSC2 + / + TSC2 - / - TSC2 - / - [R] TSC2 - / - [R] + IκBαM TSC2 IκBα actin TSC2 - / - TSC2 - / - [R] TSC2 - / - TSC2 - / - [R] NF-κB EMSA (p65/p50) MMS TNFα IL Dominant-negative IκBαM reverses TSC2 rescue of DNA damage-induced death
14 Loss of TSC2 reduces IKK and p65 activation following DNA damage TSC2 + / + TSC2 - / - MMS (min) IKKα/β-pSer 180/181 IκBα-pSer 32 actin TSC2 + / + TSC2 - / - MMS (min) p65-pser 536 p65
15 ERK1/2, but not Akt, shows sustained activation following DNA damage and TSC2 is required for ERK1/2 activation TSC2 + / + TSC2 - / - MMS (min) perk1/2-pt 183 /Y 185 perk1/2 TSC2 + / + TSC2 - / - TSC2 - / - [R] MMS perk1/2-pt 183 /Y 185 perk1/2 TSC2 + / + TSC2 - / - Unttd. EGF TPA Unttd. EGF TPA perk1/2-pt 183 /Y 185 perk1/2 TSC2 + / + TSC2 - / - TSC2 - / - [R] MMS Akt-pSer 473 Akt p38-pt 180 /Y 182 p38 EGF and TPA activation of ERK is normal TSC2-null cells
16 Rapamycin induces DNA damage resistance and restores NF-κB and ERK1/2 activation in TSC1/2-deficient MEFs TSC1 - / - TSC2 - / - Rap MMS Rap+MMS Control MMS NF-κB EMSA (p65/p50) MMS+Rap TSC2 - / - TSC2 - / - + Rap. MMS (min) perk1/2-pthr 183 /Tyr 185 perk1/2 TSC2 - / - Rapamycin effect confirms that hyperactive mtor blocks DNA damage-induced NF-κB
17 Rapamycin restores TNFα-induced Akt and NF-κB activation while LY attenuates NF-κB signaling TSC2 + / + TSC2 - / - TNFα Rap Untreated Rap TNFα Rap+TNFα Akt-pSer 473 Akt Untreated TNFα TNFα +LY Untreated Rap+TNFα Rap+TNFα +LY NF-κB EMSA (p65/p50) NF-κB EMSA (p65/p50) TSC2 - / - TSC2 + / + TSC2 - / - Akt inhibition blocks TNFα induction of NF-κB target genes
18 mtor hyperactivation inhibits NF-κB activation Loss of TSC function attenuates IKK and NF-κB activation following DNA damage and TNFα treatment, illustrating a new type of crosstalk ERK1/2 shows sustained activation following DNA damage in wild type MEFs. Lack of TSC2 decreases DNA damage but not EGF-induced ERK1/2 activation Inhibition of MEK blocks IKK and NF-κB activation by DNA damage in WT MEFs and reverses rapamycin-induced DNA damage resistance in TSCnull MEFs. PI-3 kinase inhibition reduces NF-κB signaling induced by MMS and TNFα, and reverses rapamycin-induced DNA damage resistance Akt is not significantly activated by DNA damage in MEFs. Treatment with an Akt inhibitor (A ) does not block NF-κB target gene expression or enhance MMS-induced death, implying that Akt activation is not a major survival pathway in cells with DNA damage, and that Akt activation is not needed for NF-κB activation in response to DNA damage Activation of the mtor pathway counteracts the pro-survival effects of NF-κB activation on gene expression in response to DNA damage and cytokines Ghosh et al. Cancer Cell 10:215 (2006)
19 Crosstalk between the PI-3K/Akt/TSC/mTOR pathway and NF-κB activation pathways ATM? ATM? ATM? TNFα-mediated NF-κB activation requires Akt, whereas DNA damage induction of NF-κB requires ERK - the molecular mechanisms through which mtor signaling blocks IKK activation by either pathway is unknown
20 Implications for use of mtor inhibitors in cancer therapy Many cancer cells have hyperactive mtor (e.g. due to PTEN, LKB1, TSC, PI-3K or Akt mutations, etc.), suggesting that mtor inhibitors (e.g. rapamycin analogues) could be a useful cancer therapy Inhibition of mtor in cancer cells with elevated mtor signaling leads to upregulation of signaling via IGF-1 receptor and potentially other RTKs, thereby promoting enhanced Akt survival signaling. This suggests that it may be useful to combine the use of an mtor inhibitor (e.g. rapamycin) with an inhibitor of IGF-1R, PI-3 kinase or Akt in cancer therapy Inhibition of mtor in cancer cells with elevated mtor signaling may also lead to upregulation of NF-κB activation in response to DNA damage (e.g. by chemotherapeutic agents) or cytokines. This suggests that it may be therapeutically effective to combine the use of an mtor inhibitor (e.g. rapamycin) with an inhibitor of NF-κB signaling (e.g. an IKK inhibitor)
21 The long road to the GLEEVEC TM cancer drug 1845 CML 1960 Chr 22Δ Ph Chr 1973 t(9:22) translocation 1982 Bcr-Abl (22:9) 1984 Bcr-Abl PTK activity 1990 Bcr-Abl causes CML in mice 1996 STI571 inhibits CML cell growth and v-abl tumors 1911 RSV 1927 W mutant mouse 1970 Ab-MuLV 1970 v-src gene 1952 polyoma virus 1975 c-src gene 1977 v-src protein 1977 mt antigen 1986 HZ4-FeSV 1978 v-abl protein 1978 v-src PK 1979 mt associated PTK activity 1986 v-kit PTK 1980 v-abl tyrosine kinase 1979 v-src tyrosine kinase 1983 mt associated c-src 1988 W is c-kit 1988 First PTK inhibitors reported (TKI) 1996 c-kit gof leukemia mutants 1992 CGP57148 PDGFR/ Kit/Abl TKI (Novartis) 1998 c-kit gof GIST mutants 2000 STI571/Abl structure 1998 STI571 in CML patients 2000 STI571 in GIST patients 2001 NEJM papers reporting STI571 efficacy in CML and GIST Gleevec TM approved by the FDA May 10, 2001
22 1845 CML Bennett Birchow 1960 Chr 22Δ Ph Chr Nowell Hungerford 1970 Ab-MuLV Abelson/Rabstein 1973 t(9:22) translocation Rowley 1978 v-abl protein Witte/Baltimore Reynolds/Stephenson 1982 Bcr-Abl (22:9) de Klein Stephenson Groffen Grosveld 1980 v-abl tyrosine kinase Witte/Baltimore 1984 Bcr-Abl PTK activity Konopka Witte 1990 Bcr-Abl causes CML in mice Daley/Baltimore Adams/Cory Heisterkamp/ Groffen Rosenberg/Witte 1996 STI571 inhibits CML cell growth and Bcr-Abl tumors Druker Buchdunger Lydon 2000 STI571/Abl structure Kuriyan 1911 RSV Rous 1970 v-src gene Duesberg Vogt 1952 polyoma virus Gross Eddy/Stewart 1927 W mutant mouse De Aberle 1975 c-src gene Bishop Stehelin Varmus 1977 v-src protein Brugge Erikson 1977 mt Antigen Ito/Dulbecco 1986 HZ4-FeSV/v-Kit Besmer PTK Hardy Zuckerman 1978 v-src PK Collett Erikson Bishop Varmus 1979 mt associated PTK activity Hunter/Eckhart 1987 c-kit PTK Yarden Ullrich 1979 v-src tyrosine kinase Hunter Sefton 1983 mt 1988 W is c-kit Bernstein Besmer/ Housman First PTK inhibitors (TKI) Uehara Ogawara Akiyama Graziani Umezawa Levitzki associated c-src Courtneidge/Smith 1994 c-kit gof leukemia mutants Kanakura 1992 CGP57148 PDGFR/ Kit/Abl TKI (CIBA Geigy) Lydon Matter Fabbro Buchdunger Zimmermann 1998 c-kit gof GIST mutants Kitamura 1998 STI571 in CML patients Druker Sawyers 2000 STI571 in GIST patients Demetri 2001 NEJM papers reporting STI571 efficacy in CML and GIST Druker Sawyers Demetri
Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationA particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se
A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy serves as a defence mechanism that prevents or retards
More informationSignal Transduction Pathway Smorgasbord
Molecular Cell Biology Lecture. Oct 28, 2014 Signal Transduction Pathway Smorgasbord Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Outline 1.
More informationOncogenes and Tumor. supressors
Oncogenes and Tumor supressors From history to therapeutics Serge ROCHE Neoplastic transformation TUMOR SURESSOR ONCOGENE ONCOGENES History 1911 1960 1980 2001 Transforming retrovirus RSV v-src is an oncogene
More informationTreatment for chronic myelogenous leukemia: the long road to imatinib
Review series Treatment for chronic myelogenous leukemia: the long road to imatinib Tony Hunter Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA.
More informationsupplementary information
DOI: 10.1038/ncb1875 Figure S1 (a) The 79 surgical specimens from NSCLC patients were analysed by immunohistochemistry with an anti-p53 antibody and control serum (data not shown). The normal bronchi served
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More informationIntracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining Btk activation Xingguang Liu, Zhenzhen Zhan, Dong Li, Li Xu, Feng Ma, Peng Zhang, Hangping Yao and Xuetao
More informationGrowth and Differentiation Phosphorylation Sampler Kit
Growth and Differentiation Phosphorylation Sampler Kit E 0 5 1 0 1 4 Kits Includes Cat. Quantity Application Reactivity Source Akt (Phospho-Ser473) E011054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit
More informationHoward Temin. Predicted RSV converted its genome into DNA to become part of host chromosome; later discovered reverse transciptase.
Howard Temin Predicted RSV converted its genome into DNA to become part of host chromosome; later discovered reverse transciptase Nobel prize 1975 Figure 3.6 The Biology of Cancer ( Garland Science 2007)
More informationPhospho-AKT Sampler Kit
Phospho-AKT Sampler Kit E 0 5 1 0 0 3 Kits Includes Cat. Quantity Application Reactivity Source Akt (Ab-473) Antibody E021054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit Akt (Phospho-Ser473) Antibody
More informationVirchow s Hypothesis lymphorecticular infiltration of cancer reflected the origin of cancer at sites of inflammation
Virchow s Hypothesis 1863 lymphorecticular infiltration of cancer reflected the origin of cancer at sites of inflammation Barrett s esophagus/ Esophageal adenocarcinoma PSC / Cholangiocarcinoma Viral hepatitis
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationSupplementary Material
Supplementary Material The Androgen Receptor is a negative regulator of eif4e Phosphorylation at S209: Implications for the use of mtor inhibitors in advanced prostate cancer Supplementary Figures Supplemental
More informationDeregulation of signal transduction and cell cycle in Cancer
Deregulation of signal transduction and cell cycle in Cancer Tuangporn Suthiphongchai, Ph.D. Department of Biochemistry Faculty of Science, Mahidol University Email: tuangporn.sut@mahidol.ac.th Room Pr324
More informationActivation of cellular proto-oncogenes to oncogenes. How was active Ras identified?
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
More informationSignal transduction and protein kinase inhibitors. Feng Qian ( 钱峰 )
Signal transduction and protein kinase inhibitors Feng Qian ( 钱峰 ) fengqian@sjtu.edu.cn Protein Kinases in the Human Genome 518 kinases 1.7 % of human genome Lipid kinases Nucleotide kinases Cell Signaling
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationDetermination Differentiation. determinated precursor specialized cell
Biology of Cancer -Developmental Biology: Determination and Differentiation -Cell Cycle Regulation -Tumor genes: Proto-Oncogenes, Tumor supressor genes -Tumor-Progression -Example for Tumor-Progression:
More informationReceptor mediated Signal Transduction
Receptor mediated Signal Transduction G-protein-linked receptors adenylyl cyclase camp PKA Organization of receptor protein-tyrosine kinases From G.M. Cooper, The Cell. A molecular approach, 2004, third
More informationUSP10 inhibits genotoxic NF-κB activation by MCPIP1- facilitated deubiquitination of NEMO
Manuscript EMBO-2013-84573 USP10 inhibits genotoxic NF-κB activation by MCPIP1- facilitated deubiquitination of NEMO Jixiao Niu, Yuling Shi, Jingyan Xue, Ruidong Miao, Shengping Huang, Tianyi Wang, Jiong
More informationAge Disparity in the Dissemination of Imatinib Mesylate (Gleevec) for Treating Chronic Myeloid Leukemia
Age Disparity in the Dissemination of Imatinib Mesylate (Gleevec) for Treating Chronic Myeloid Leukemia Chuck Wiggins, Ph.D. Director and Principal Investigator New Mexico Tumor Registry North American
More informationProtein tyrosine kinase signaling
rotein tyrosine kinase signaling Serge ROCHE CRBM CNRS/Montpellier University serge.roche@crbm.cnrs.fr rotein phosphorylation on Tyr A central mechanism to control cell communication in a multicellular
More informationNNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update
NNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update 1 Overview The natural growth factor IGF-1 is broken down in the body to IGF-1[1-3] NNZ-2566 is an analogue of IGF-1[1-3] developed
More informationKaryotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl
Chapt. 18 Cancer Molecular Biology of Cancer Student Learning Outcomes: Describe cancer diseases in which cells no longer respond Describe how cancers come from genomic mutations (inherited or somatic)
More informationDox. R26-rtTA Tyr-CreERT2. any ink/arf, no rtta (n=8) ink/arf +/+ (n=5) Day 0 Day 11 Day 18 Day 28
A 4OHT Dox hraf iip tumors inras ddh 2 O -RT Ink/Arf / Pten l/ l R26-lsl-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF V6E Ink/Arf / Pten / R26-rtTA Tyr-reERT2 TetO-hRAF
More informationWhat causes cancer? Physical factors (radiation, ionization) Chemical factors (carcinogens) Biological factors (virus, bacteria, parasite)
Oncogenes What causes cancer? Chemical factors (carcinogens) Physical factors (radiation, ionization) Biological factors (virus, bacteria, parasite) DNA Mutation or damage Oncogenes Tumor suppressor genes
More informationSUPPLEMENTAL FIGURE LEGENDS
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure S1: Endogenous interaction between RNF2 and H2AX: Whole cell extracts from 293T were subjected to immunoprecipitation with anti-rnf2 or anti-γ-h2ax antibodies
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationGenome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department
Genome of Hepatitis B Virus VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department Proto Oncogen and Oncogen Oncogen Proteins that possess the ability to cause
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Cell sphingolipids and S1P bound to endogenous TRAF2. Sphingolipid Cell pmol/mg TRAF2 immunoprecipitate pmol/mg Sphingomyelin 4200 ± 250 Not detected Monohexosylceramide 311 ± 18
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationStructure and Function of Fusion Gene Products in. Childhood Acute Leukemia
Structure and Function of Fusion Gene Products in Childhood Acute Leukemia Chromosomal Translocations Chr. 12 Chr. 21 der(12) der(21) A.T. Look, Science 278 (1997) Distribution Childhood ALL TEL-AML1 t(12;21)
More informationCell cycle, signaling to cell cycle, and molecular basis of oncogenesis
Cell cycle, signaling to cell cycle, and molecular basis of oncogenesis MUDr. Jiří Vachtenheim, CSc. CELL CYCLE - SUMMARY Basic terminology: Cyclins conserved proteins with homologous regions; their cellular
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationCancer. Death Rates for the Main Causes of Death in the U.S. Leading Sites of New Cases & Deaths (2015 estimates in the U.S.)
11/25/17 Learning Goals for This Lecture Cancer - To recognize that cancer largely is a preventable disease. - To recognize that cancer is a disease of our own genes. Weimin Zhong, Ph.D. weimin.zhong@yale.edu
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:1.138/nature9814 a A SHARPIN FL B SHARPIN ΔNZF C SHARPIN T38L, F39V b His-SHARPIN FL -1xUb -2xUb -4xUb α-his c Linear 4xUb -SHARPIN FL -SHARPIN TF_LV -SHARPINΔNZF -SHARPIN
More informationAACR 101st Annual Meeting 2010, Washington D.C. Experimental and Molecular Therapeutics Section 29; Abstract #3855
Investigation of the Growth Inhibitory Activity of the MEK Inhibitor ARRY-162 in Combination with Everolimus in a Variety of KRas and PI3K Pathway Mutant Cancers Brian Tunquist, Tyler Risom, Debbie Anderson,
More informationKEY CONCEPT QUESTIONS IN SIGNAL TRANSDUCTION
Signal Transduction - Part 2 Key Concepts - Receptor tyrosine kinases control cell metabolism and proliferation Growth factor signaling through Ras Mutated cell signaling genes in cancer cells are called
More information609G: Concepts of Cancer Genetics and Treatments (3 credits)
Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationTitle: Cytosolic DNA-mediated, STING-dependent pro-inflammatory gene. Fig. S1. STING ligands-mediated signaling response in MEFs. (A) Primary MEFs (1
1 Supporting Information 2 3 4 Title: Cytosolic DNA-mediated, STING-dependent pro-inflammatory gene induction necessitates canonical NF-κB activation through TBK1 5 6 Authors: Abe et al. 7 8 9 Supporting
More informationSignaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research
Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How
More informationContents. Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX
Contents Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX 1 General Aspects of Signal Transduction and Cancer Therapy 1 1.1 General Principles of Signal Transduction
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More informationPrinciples of Genetics and Molecular Biology
Cell signaling Dr. Diala Abu-Hassan, DDS, PhD School of Medicine Dr.abuhassand@gmail.com Principles of Genetics and Molecular Biology www.cs.montana.edu Modes of cell signaling Direct interaction of a
More informationS1a S1b S1c. S1d. S1f S1g S1h SUPPLEMENTARY FIGURE 1. - si sc Il17rd Il17ra bp. rig/s IL-17RD (ng) -100 IL-17RD
SUPPLEMENTARY FIGURE 1 0 20 50 80 100 IL-17RD (ng) S1a S1b S1c IL-17RD β-actin kda S1d - si sc Il17rd Il17ra rig/s15-574 - 458-361 bp S1f S1g S1h S1i S1j Supplementary Figure 1. Knockdown of IL-17RD enhances
More informationThink Tank on Molecular Targets: Survival and Death Pathways in Cancer
Think Tank on Molecular Targets: Survival and Death Pathways in Cancer Oncogenes Induce Cell Proliferation & Cell Death Proliferation Mitogens ONCOGENES Apoptosis Adapted from G Evan Survival Signals Block
More informationCells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2)
Supplemental Methods Cells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2) podocytes were cultured as described previously. Staurosporine, angiotensin II and actinomycin D were all obtained
More informationSelecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
More informationMolecular Medicine: Gleevec and Chronic Myelogenous Leukemia
Molecular Medicine: Gleevec and Chronic Myelogenous Leukemia Dec 14 & 19, 2006 Prof. Erin Shea Prof. Dan Kahne Cancer, Kinases and Gleevec: 1. What is CML? a. Blood cell maturation b. Philadelphia Chromosome
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationT Cell Effector Mechanisms I: B cell Help & DTH
T Cell Effector Mechanisms I: B cell Help & DTH Ned Braunstein, MD The Major T Cell Subsets p56 lck + T cells γ δ ε ζ ζ p56 lck CD8+ T cells γ δ ε ζ ζ Cα Cβ Vα Vβ CD3 CD8 Cα Cβ Vα Vβ CD3 MHC II peptide
More informationSupplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation.
Supplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation. (a) Embryonic fibroblasts isolated from wildtype (WT), BRAF -/-, or CRAF -/- mice were irradiated (6 Gy) and DNA damage
More informationWilliam C. Comb, Jessica E. Hutti, Patricia Cogswell, Lewis C. Cantley, and Albert S. Baldwin
Molecular Cell, Volume 45 Supplemental Information p85 SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation William C. Comb, Jessica E. Hutti,
More informationBIO360 Fall 2013 Quiz 1
BIO360 Fall 2013 Quiz 1 1. Examine the diagram below. There are two homologous copies of chromosome one and the allele of YFG carried on the light gray chromosome has undergone a loss-of-function mutation.
More informationSupplementary Information. Table of contents
Supplementary Information Table of contents Fig. S1. Inhibition of specific upstream kinases affects the activity of the analyzed readouts Fig. S2. Down-regulation of INCENP gene induces the formation
More informationChapt 15: Molecular Genetics of Cell Cycle and Cancer
Chapt 15: Molecular Genetics of Cell Cycle and Cancer Student Learning Outcomes: Describe the cell cycle: steps taken by a cell to duplicate itself = cell division; Interphase (G1, S and G2), Mitosis.
More informationPhospholipase C γ Prof. Graham Carpenter
Graham Carpenter, h.d. rofessor of Biochemistry Cornelia Crooke Department of Biochemistry Vanderbilt University School of Medicine, Nashville, TN 1 Receptor Tyrosine Kinases GF Extracellular M Intracellular
More informationMolecular Hematopathology Leukemias I. January 14, 2005
Molecular Hematopathology Leukemias I January 14, 2005 Chronic Myelogenous Leukemia Diagnosis requires presence of Philadelphia chromosome t(9;22)(q34;q11) translocation BCR-ABL is the result BCR on chr
More informationChapter 18- Oncogenes, tumor suppressors & Cancer
Chapter 18- Oncogenes, tumor suppressors & Cancer - Previously we have talked about cancer which is an uncontrolled cell proliferation and we have discussed about the definition of benign, malignant, metastasis
More informationSrc-INACTIVE / Src-INACTIVE
Biology 169 -- Exam 1 February 2003 Answer each question, noting carefully the instructions for each. Repeat- Read the instructions for each question before answering!!! Be as specific as possible in each
More informationBiol403 MAP kinase signalling
Biol403 MAP kinase signalling The mitogen activated protein kinase (MAPK) pathway is a signalling cascade activated by a diverse range of effectors. The cascade regulates many cellular activities including
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino From the nucleus to the mitochondria and backthe odyssey of a multitask STAT3 This is the author's manuscript Original Citation: From
More informationOrigin of oncogenes? Oncogenes and Proto-oncogenes. Jekyll and Hyde. Oncogene hypothesis. Retroviral oncogenes and cell proto-oncogenes
Oncogenes and Proto-oncogenes Jekyll and Hyde A double edged sword Origin of oncogenes? Oncogene hypothesis Retroviral oncogenes and cell proto-oncogenes (v-onc) (c-onc) The role of c-onc in cancer How
More informationp53 and Apoptosis: Master Guardian and Executioner Part 2
p53 and Apoptosis: Master Guardian and Executioner Part 2 p14arf in human cells is a antagonist of Mdm2. The expression of ARF causes a rapid increase in p53 levels, so what would you suggest?.. The enemy
More informationPlanar Waveguides: How Nano Layers Enable to Detect Zepto Moles of Macro Molecules in Pico Liter Spots on Micro Arrays
Planar Waveguides: How Nano Layers Enable to Detect Zepto Moles of Macro Molecules in Pico Liter Spots on Micro Arrays Dr. Markus Ehrat Zeptosens A Division of Bayer Schweiz AG SSOM Meeting March 16 /17
More informationLecture 7: Signaling Through Lymphocyte Receptors
Lecture 7: Signaling Through Lymphocyte Receptors Questions to Consider After recognition of its cognate MHC:peptide, how does the T cell receptor activate immune response genes? What are the structural
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationFrontiers in Cancer Therapy. John Glod, M.D., Ph.D.
Frontiers in Cancer Therapy John Glod, M.D., Ph.D. September 15, 2017 Objectives The Past: Alkylating agents The Present: Tyrosine Kinase Inhibitors The Future: Gene Expression, Metabolic cancers, CAR
More informationciap using fragment based drug discovery
Discovery of a potent dual antagonist of both XIAP and ciap using fragment based drug discovery Gianni Chessari, PhD TAT Congress 2012 Disclosures I am an employee of Astex Pharmaceuticals I will present
More informationTITLE: A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis
AD Award Number: W81XWH-05-1-0164 TITLE: A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis PRINCIPAL INVESTIGATOR: Fuyuhiko Tamanoi, Ph.D. CONTRACTING ORGANIZATION: The University
More informationLysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease Linda Xiaoyan Li,, Julien Sage, Xiaogang Li J Clin Invest. 2017;127(7):2751-2764. https://doi.org/10.1172/jci90921.
More informationSignal Transduction Pathways in Human Diseases
Molecular Cell Biology Lecture. Oct 29, 2015 Signal Transduction Pathways in Human Diseases Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Introduction
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationReceived 28 September 2010/Returned for modification 19 October 2010/Accepted 27 April 2011
MOLECULAR AND CELLULAR BIOLOGY, July 2011, p. 2774 2786 Vol. 31, No. 14 0270-7306/11/$12.00 doi:10.1128/mcb.01139-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. A Cytosolic
More informationSupporting Information. FADD regulates NF-кB activation and promotes ubiquitination of cflip L to induce. apoptosis
1 2 Supporting Information 3 4 5 FADD regulates NF-кB activation and promotes ubiquitination of cflip L to induce apoptosis 6 7 Kishu Ranjan and Chandramani Pathak* 8 9 Department of Cell Biology, School
More informationInterrogating mtor Inhibition in Patients with HRPC
Interrogating mtor Inhibition in Patients with HRPC Daniel George, John Madden, Andrew Armstrong, Mark Dewhirst, Nancy Major, and Phillip Febbo Divisions of Medical Oncology, Urology, Pathology, Radiology,
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationE3 ligase TRIM72 negatively regulates myogenesis by IRS-1 ubiquitination
E3 ligase negatively regulates myogenesis by IRS-1 ubiquitination Young-Gyu Ko College of Life Science and Biotechnology Korea University MyHC immunofluorescence Lipid rafts are plasma membrane compartments
More informationSupplementary Figure 1
Supplementary Figure 1 Constitutive EGFR signaling does not activate canonical EGFR signals (a) U251EGFRInd cells with or without tetracycline exposure (24h, 1µg/ml) were treated with EGF for 15 minutes
More informationINVESTIGATING THE ROLE OF IKKε. CANCER-ASSOCIATED NF-κB ACTIVITY. Mezher Adli. Chapel Hill 2007
INVESTIGATING THE ROLE OF IKKε (EPSILON) IN CANCER-ASSOCIATED NF-κB ACTIVITY Mezher Adli A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment
More informationNegative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α
Negative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α Mahnaz Janghorban, PhD Dr. Rosalie Sears lab 2/8/2015 Zanjan University Content 1. Background (keywords: c-myc, PP2A,
More informationMechanisms Associated with Dietary Energy Balance Effects on Tumor Development: Alterations in Growth Factor and Energy Sensing Pathways
Mechanisms Associated with Dietary Energy Balance Effects on Tumor Development: Alterations in Growth Factor and Energy Sensing Pathways John DiGiovanni, Ph.D. Professor and Coulter R. Sublett Endowed
More informationSupplementary Figure 1 CD4 + T cells from PKC-θ null mice are defective in NF-κB activation during T cell receptor signaling. CD4 + T cells were
Supplementary Figure 1 CD4 + T cells from PKC-θ null mice are defective in NF-κB activation during T cell receptor signaling. CD4 + T cells were isolated from wild type (PKC-θ- WT) or PKC-θ null (PKC-θ-KO)
More informationIntroduction: 年 Fas signal-mediated apoptosis. PI3K/Akt
Fas-ligand (CD95-L; Fas-L) Fas (CD95) Fas (apoptosis) 年 了 不 度 Fas Fas-L 力 不 Fas/Fas-L T IL-10Fas/Fas-L 不 年 Fas signal-mediated apoptosis 度降 不 不 力 U-118, HeLa, A549, Huh-7 MCF-7, HepG2. PI3K/Akt FasPI3K/Akt
More informationYong Wu, Ph.D. Division of Cancer Research and Training (DCRT) Charles R. Drew University of Medicine & Science
Yong Wu, Ph.D. Division of Cancer Research and Training (DCRT) Charles R. Drew University of Medicine & Science Jay Vadgama, Ph.D Chief, Division of Cancer Research and Training Background One in 8 women
More informationPredictive PP1Ca binding region in BIG3 : 1,228 1,232aa (-KAVSF-) HEK293T cells *** *** *** KPL-3C cells - E E2 treatment time (h)
Relative expression ERE-luciferase activity activity (pmole/min) activity (pmole/min) activity (pmole/min) activity (pmole/min) MCF-7 KPL-3C ZR--1 BT-474 T47D HCC15 KPL-1 HBC4 activity (pmole/min) a d
More informationSupplements. Figure S1. B Phalloidin Alexa488
Supplements A, DMSO, PP2, PP3 Crk-myc Figure S1. (A) Src kinase activity is necessary for recruitment of Crk to Nephrin cytoplasmic domain. Human podocytes expressing /7-NephrinCD () were treated with
More informationControl of Cell Proliferation by Peptide Growth Factors. Autocrine Growth Factor Production Causes Malignant Transformation?
Control of Cell Proliferation by Peptide Growth Factors Autocrine Growth Factor Production Causes Malignant Transformation? Transforming Activities From Condition Media from a Tumor Cell Line Condition
More informationCyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells
Research article Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells Paul T. Brinkkoetter, 1 Paul Olivier, 2 Jimmy S. Wu, 1 Scott Henderson, 1 Ronald D. Krofft,
More informationTITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway
AWARD NUMBER: W81XWH-12-1-0560 TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway PRINCIPAL INVESTIGATOR: Andrew S. Kraft, MD CONTRACTING ORGANIZATION:
More informationSupplementary Figure 1
Supplementary Figure 1 Dox Cis Cam Pac 0 15 1 15 1 15 1 15 1 15 µmole/l Ub p53 Cytotoxic anticancer agents increase p53 levels but do not generally promote the accumulation of ubiquitinated. Western blots
More informationNFκB What is it and What s the deal with radicals?
The Virtual Free Radical School NFκB What is it and What s the deal with radicals? Emily Ho, Ph.D Linus Pauling Institute Scientist Department of Nutrition and Food Management Oregon State University 117
More informationRAW264.7 cells stably expressing control shrna (Con) or GSK3b-specific shrna (sh-
1 a b Supplementary Figure 1. Effects of GSK3b knockdown on poly I:C-induced cytokine production. RAW264.7 cells stably expressing control shrna (Con) or GSK3b-specific shrna (sh- GSK3b) were stimulated
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationNucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress
Jean Y. J. WANG MINIREVIEW Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress Jean Y. J. WANG * Division of Biological Sciences and Moores Cancer Center, University
More informationSupplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
More information